Tesamorelin Effects on Liver Fat and Histology in HIV

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-01

Study Completion Date

2019-07-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Liver disease is one of the leading co-morbidities of human immunodeficiency virus (HIV) infection, and nonalcoholic fatty liver disease (NAFLD) is present in approximately 30-40% of patients with HIV infection. Nonalcoholic steatohepatitis (NASH) is a more severe form of NAFLD in which increased liver fat is also accompanied by inflammation, cellular damage, and fibrosis.

NAFLD is most prevalent in patients who also have increased visceral adiposity, and our group has previously shown that HIV-infected individuals with increased visceral adiposity generally have decreased growth hormone secretion. Tesamorelin is a growth hormone releasing hormone (GHRH) analogue that increases endogenous growth hormone secretion. Tesamorelin is FDA-approved for the reduction of visceral fat in HIV-infected individuals. In a previous study, treatment with tesamorelin in HIV-infected individuals selected for abdominal adiposity reduced liver fat. The current study is designed to test the effect of tesamorelin on liver fat and steatohepatitis in HIV-infected individuals who have NAFLD. The investigators hypothesize that tesamorelin will reduce liver fat and will also ameliorate the inflammation, fibrosis, and hepatocellular damage seen in conjunction with NASH.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

NCT07143968

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease HIV (Human Immunodeficiency Virus)

NOT_YET_RECRUITING PHASE2

Effects of Growth Hormone Releasing Hormone in HIV

NCT01263717

HIV HIV Lipodystrophy

COMPLETED NA

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

NCT06554717

HIV-1-infection Frailty Impaired Physical Function +2 more

RECRUITING PHASE2

Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV

NCT04795219

NAFLD NAFLD-HIV Hiv

RECRUITING

Body Composition and Adipose Tissue in HIV

NCT03226821

HIV Lipodystrophy Syndrome Growth Hormone Deficiency Body Composition

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Immunodeficiency Virus (HIV) Nonalcoholic Fatty Liver Disease (NAFLD) Nonalcoholic Steatohepatitis (NASH)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tesamorelin

tesamorelin 2mg subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.

Group Type EXPERIMENTAL

tesamorelin

Intervention Type DRUG

Placebo

placebo subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

inactive substance that looks like tesamorelin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tesamorelin

Intervention Type DRUG

Placebo

inactive substance that looks like tesamorelin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Egrifta

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women 18-70yo
* HIV-infection and treatment with a stable antiretroviral regimen for ≥ 6 months
* Hepatic steatosis as demonstrated by liver fat fraction ≥5% on 1H-MRS
* Hepatitis C antibody negative, or, if Hepatitis C antibody positive, either: a) known clinical disease, successful therapy ≥1 year prior to baseline and undetectable HCV RNA, or b) HCV resolved spontaneously and undetectable HCV RNA. Hepatitis B surface antigen negative at screen visit
* For females ≥50yo, negative mammogram within 1 year of baseline visit
* If use of Vitamin E ≥400 IU daily (in any formulation), stable dose for ≥6 months prior to study.

Exclusion Criteria

* Heavy alcohol use defined as consumption of more than 20g daily for women or more than 30g daily for men for at least 3 consecutive months over the past 5 years
* Use of insulin or thiazoledinediones (TZDs), or HbA1c ≥7%. Individuals with mild diabetes that is well-controlled with diet and/or oral anti-diabetic agents besides TZDs will be included. Use of oral anti-diabetics must have been stable for ≥6 months prior to study entry.
* Known diabetic retinopathy.
* Known cirrhosis, or Child-Pugh score ≥7, stage 4 fibrosis on biopsy, or clinical evidence of cirrhosis or portal hypertension on imaging or exam.
* Chronic corticosteroid use except intermittent use of topical steroid creams and/or prior short-term physiologic corticosteroid use in the ≤ 6 months prior to baseline visit
* Chronic use of methotrexate, amiodarone, or tamoxifen
* Known diagnosis of Alpha-1 antitrypsin deficiency, Wilson's disease, hemochromatosis, or autoimmune hepatitis
* Use of GH or GHRH within the past 1 year
* Change in lipid lowering or anti-hypertensive regimen within 3 months of screening
* HgB \< 11.0 g/dL, CD4 \< 100 th/mm3, or HIV viral load \> 400 copies/mL
* Active malignancy
* For men, history of prostate cancer or evidence of prostate malignancy by PSA \> 5 ng/mL
* Severe chronic illness judged by the investigator to present a contraindication to participation
* History of hypopituitarism, head irradiation or any other condition known to affect the GH axis
* Use of physiologic testosterone (men) or estrogen or progesterone (women) unless stable use for a year or more prior to study entry
* Previous weight loss surgery
* For women, positive pregnancy test performed in a CLIA certified laboratory using a test with a sensitivity of at least 25mIU/mL, or breastfeeding.
* Known hypersensitivity to tesamorelin or mannitol
* Unwillingness to abstain from the conception process during the study (i.e., must agree not to participate in an active attempt to become pregnant or impregnate, donate sperm, or participate in in vitro fertilization)
* Unwillingness to use one (for males) or two (for females) reliable methods of contraception while engaging in heterosexual intercourse during the study. Acceptable methods for women include hormonal contraception (estrogen/progesterone or progesterone-only formulations) if stable for a year or more prior to study entry, intrauterine device, or barrier methods (condom, or diaphragm with spermicide). Acceptable methods for males include condom use. This requirement does not apply to women who have been post-menopausal for at least 24 consecutive months or have undergone surgical sterilization, or to men who have undergone surgical sterilization or have documented azoospermia.
* Not willing or able to adhere to dose schedules and required procedures per protocol

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No